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Malignant neoplasms frequently induce a progressive loss of lean
body mass in the host, associated with marked alterations in
endocrine and metabolic homeostasis. Skeletal muscle tissue,
which accounts for almost half of the whole body protein mass, is
severely affected in cancer cachexia (Lawson et al, 1982;
Morrison, 1989; Tisdale, 1992). Muscle wasting in cachexia is
associated with enhanced protein turnover rates (Kien and
Camitta, 1983; 1987; Beck and Tisdale, 1989; Melville et al, 1990;
Beck et al, 1991). In addition, cachexia tends to develop at rather
late stages of neoplastic disease. Thus, preventing muscle wasting
in cancer patients is of great potential clinical interest. Whether the
negative protein balance results from altered rates of synthesis or
breakdown or from changes on both sides of muscle protein
turnover remains unclear (Lundholm et al, 1979; Emery et al,
1982; Pain et al, 1984; Tessitore et al, 1987a).
The Yoshida AH-130 rat ascites hepatoma is a suitable model
system for studying the mechanisms involved in the establishment
of cachexia. Its growth in the host causes rapid and progressive loss
of body weight and tissue wasting, particularly in skeletal muscle.
Acceleration of tissue protein breakdown accounts for most of the
wasting in AH-130 bearers (Baccino et al, 1986; Tessitore et al,
1986; 1987a; 1993a). In particular, skeletal muscle hypercatabo-
lism involves hyperactivation of the ATP-ubiquitin-dependent
proteolytic system (Llovera et al, 1994). Detectable plasma levels
of tumour necrosis factor-a(TNF) and perturbations in hormonal
homeostasis (Tessitore et al, 1993b) may play an important role in
forcing metabolic balance towards the catabolic side.
Interleukin-15 (IL-15) is a novel cytokine first identified in the
supernatant of the monkey epithelial cell line CV-1/EBNA as a
factor capable of stimulating T-cell activity (Grabstein et al, 1994),
and enhancing their antitumour properties (Munger et al, 1995).
Indeed, IL-15 induces T-cell proliferation (Bruton et al, 1994),
enhances natural killer (NK) cell activity, upregulates production
of NK-cell-derived cytokines, including g-interferon (g-IFN),
granulocyte/macrophage-colony stimulating factor (GM-CSF) and
TNF (Carson et al, 1994), and promotes NK cell survival (Carson
et al, 1997). In addition, it stimulates proliferation and differentia-
tion of B cells activated by anti-immunoglobulin M antibodies
(Armitage et al, 1995) and may protect T cells and neutrophils
from apoptosis (Akbar et al, 1996; Girard et al, 1996), being a
potent inhibitor of apoptosis both in vitro and in vivo (Bulfone-
Paus et al, 1997). Despite the lack of significant sequence
homology, IL-15 shares many biological activities with IL-2 since
its function are mediated through the band gchains of the IL-2
receptor (Giri et al, 1994). However, unlike IL-2, which is
produced almost exclusively by activated T cells, the IL-15 gene is
not expressed in these cells (Grabstein et al, 1994), but rather IL-
15 mRNA has been detected in placenta, skeletal muscle, kidney,
lung, heart (Grabstein et al, 1994) and intestinal epithelial cells
(Reinecker et al, 1996).
Recently, Quinn et al (1995) have proposed an important role for
IL-15 in skeletal muscle. Indeed, IL-15 can stimulate differentiated
myocytes and muscle fibres to accumulate increased amounts of
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Summar yTissue protein hypercatabolism (TPH) is an important feature in cancer cachexia, particularly with regard to the skeletal muscle.
The Yoshida AH-130 rat ascites hepatoma is a model system for studying the mechanisms involved in the processes that lead to tissue
depletion, since it induces in the host a rapid and progressive muscle wasting, primarily due to TPH. The present study was aimed at
investigating if IL-15, which is known to favour muscle fibre hypertrophy, could antagonize the enhanced muscle protein breakdown in this
cancer cachexia model. Indeed, IL-15 treatment partly inhibited skeletal muscle wasting in AH-130-bearing rats by decreasing (8-fold) protein
degradative rates (as measured by 14C-bicarbonate pre-loading of muscle proteins) to values even lower than those observed in non-tumour-
bearing animals. These alterations in protein breakdown rates were associated with an inhibition of the ATP-ubiquitin-dependent proteolytic
pathway (35% and 41% for 2.4 and 1.2kb ubiquitin mRNA, and 57% for the C8 proteasome subunit, respectively). The cytokine did not
modify the plasma levels of corticosterone and insulin in the tumour hosts. The present data give new insights into the mechanisms by which
IL-15 exerts its preventive effect on muscle protein wasting and seem to warrant the implementation of experimental protocols involving the
use of the cytokine in the treatment of pathological states characterized by TPH, particularly in skeletal muscle, such as in the present model
of cancer cachexia. ©2000 Cancer Research Campaign
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contractile proteins (Quinn et al, 1995), suggesting that IL-15 may
play a role in skeletal muscle fibre growth in vivo. Bearing all this
in mind, it was the aim of the present investigation to assess the
effects of IL-15 administration on the skeletal muscle protein
turnover in rats bearing a cachexia-generating, fast-growing
tumour.
MATERIALS AND METHODS
Animals, tumour inoculation and treatment
Male Wistar rats (Interfauna, Barcelona, Spain) weighing approxi-
mately 110–135g were utilized. The animals were maintained on
a regular light–dark cycle (light from 8 am to 8 pm) and had free
access to food and water. The diet (Panlab, Barcelona, Spain)
consisted of 54% carbohydrate, 17% protein and 5% fat (the
residue was non-digestible material). Rats were divided into two
groups, controls and tumour hosts. The latter received an intraperi-
toneal inoculum of 108 AH-130 Yoshida ascites hepatoma cells
obtained from exponential tumours (for details see Tessitore et al,
1987a). Both groups were further divided into treated and
untreated, the former being administered a daily s.c. dose of IL-15
(100m g kg–1 b.w. dissolved in physiological saline solution), the
latter a corresponding volume of vehicle.
On days 0, 4, and 7 after tumour transplantation, animals were
weighed and anaesthesized with diethyl ether. The tumour was
harvested from the peritoneal cavity, its volume and cellularity
evaluated. Blood was collected from the abdominal aorta into
heparinized tubes and centrifuged (3500g, 10min, 4°C) to obtain
plasma. Tissues were rapidly excised, weighed, and frozen in
liquid nitrogen (Tessitore et al, 1987a; 1993a).
Protein turnover
Protein turnover rates were determined by a method that, as previ-
ously discussed (Tessitore et al, 1987a, 1993a), offers the best
compromise for monitoring protein synthesis and degradation
simultaneously in the same animal (Garlick et al, 1975). Briefly,
apparent rates of synthesis and degradation for proteins of the slow
turnover pool were evaluated by measuring the decay in specific
and total protein radioactivity in tibialis muscles after labeling in
vivo, 24h before tumour transplantation, with a single intraperi-
toneal dose of sodium 14C-bicarbonate (250m Ci kg–1 b.w.). Four
days after tumour inoculation, fractional rates of protein degrada-
tion (kd), synthesis (ks), and accumulation (ka) were calculated as
follows and expressed as % per day:
kd = ln(total protein radioactivity)/t
ks = ln(specific protein radioactivity)/t
ka = ln(total protein)/t
Muscle protein extraction was carried out by using a
trichloroacetic acid precipitation method, as previously described
(Costelli et al, 1993). Tissue protein was determined by the
method of Bradford (1976), using bovine serum albumin as
working standard.
RNA isolation and Northern blot analysis
Total RNA from tibialis muscle was extracted using the 
acid guanidinium isothiocyanate/phenol/chloroform method as
described by Chomczynski and Sacchi (1987). RNA samples 
(20m g) were denatured, subjected to 1.2% agarose gel elec-
trophoresis and transferred to Hybond N membrane (Amersham).
RNA was fixed to the membranes by Genelinker (Biorad).
The RNA in gel and filters was visualized with ethidium
bromide and photographed by UV transillumination to ensure the
integrity of RNA, to check the loading of equivalent amounts of
RNA and to confirm proper transfer. RNA was trasferred in 20´
standard saline citrate (SSC: 0.15M NaCl and 15mM sodium
citrate, pH 7.0). Hybridization was done at 65°C overnight in the
hybridization buffer (0.25M Na2HPO4, 7% SDS, 1mM EDTA,
1% BSA, 10% dextran sulphate), and denatured labelled probes
(106–107 cpm ml–1) were added.
Radiolabelled probes were prepared by the random priming
method (Boehringer-Mannheim). The ubiquitin probe used was a
cDNA clone containing 12 base pairs of the second ubiquitin
coding sequence plus a complete third and fourth ubiquitin coding
sequence and 120 base pairs of the 3¢ -untranslated region of the
chicken polyubiquitin gene UB1 (Bond and Schlesinger, 1985).
The C8 proteasome subunit probe used was a cDNA clone
containing 850 base pairs of the rat C8 proteasome gene (Tanaka et
al, 1990). UV light-illuminated ethidium bromide staining of the
28S rRNA was used as a control of loading. Filters were exposed
to Hyperfilm-MP films (Amersham) at –80°C for 2–4 days and
quantified by scanning densitometry.
Plasma hormones
Circulating corticosterone was evaluated by a rat radioim-
munoassay (IDS, Boldon, England). Insulin was measured by
radioimmunoassay by the method of Albano et al (1972), using rat
insulin as working standard.
Data presentation
Data are given as means ±SEM Student’s t-test was used to calcu-
late the significance of differences.
Chemicals
All enzymes and coenzymes were obtained from Boehringer-
Mannheim (Barcelona, Spain) or Sigma (St. Louis, MO, USA),
sodium  14C-bicarbonate (53mCi mmol–1) from New England
Nuclear (Boston, MA, USA). Recombinant human IL-15 was
kindly provided by Immunex Corporation (Seattle, Washington,
USA).
RESULTS
The Yoshida AH-130 rat ascites hepatoma grew exponentially for
4–5 days then shifted into a stationary phase approximately 7 days
after transplantation, as previously shown (Tessitore et al, 1987b).
Tumour growth was not significantly affected by IL-15 (Table 1).
As shown in Table 1, the loss of body weight in tumour bearers
became clear by day 7 and was less marked in the IL-15-treated
tumour-bearing group. A reduction of white adipose tissue mass
was detectable at day 4 in IL-15-treated controls; this tissue was
also diminished in tumour bearers (both at days 4 and 7), yet not
further affected to a significant degree by the cytokine treatment.
Liver was hypotrophic 4 days after tumour inoculation and even
more so by day 7, when a significant protective effect exerted by
IL-15 on this tissue was observed.
© 2000 Cancer Research CampaignQuite different was the pattern with regard to skeletal muscle. A
decrease in wet weight (Table 2) and protein content (Table 3) was
elicited by tumour growth, as previously reported (Tessitore et al,
1987a). Treatment with IL-15 partially prevented the protein
waste in tibialis muscle (Table 3). This protective effect was also
noticeable in terms of wet tissue weight for the skeletal muscles
(Table 2). In agreement with previous observations (Carbó et al,
2000), IL-15 did not exert any trophic action (weight or protein
increase) on muscles in non-tumour bearers (Tables 2 and 3).
Protein turnover in tibialis muscle 4 days after tumour inocula-
tion was evaluated to determine if the protein-sparing action of 
IL-15 was exerted by changes in muscle protein degradation or
synthesis, or both (Table 4). As previously reported (Tessitore et
al, 1987a, 1993a), rates of tibialis muscle protein degradation were
enhanced (48%) as a consequence of tumour growth, while muscle
protein synthesis remained virtually unchanged, resulting in
protein accumulation rates lower (27%) than in controls (Table 4).
On treatment with IL-15, the elevation of protein breakdown rates
was suppressed and protein accumulation rates returned to levels
similar to those in controls (Table 4). No detectable effect was
observed with regard to protein synthesis rates. In non-tumour
bearers, IL-15 treatment resulted in a decrease in protein degradation
528 N Carbó et al
British Journal of Cancer (2000) 83(4), 526–531 © 2000 Cancer Research Campaign
Table 1 Body and tissue weight and tumour growth in AH-130 hosts
Time Tumour Treatment Body weight (g) Liver WAT BAT Total tumour Tumour
(mg) (mg) (mg) cell number volume
initial final (´ 106) (ml)
day 4 no none 131 ± 4 166 ± 5 5850 ± 177 749 ± 32 149 ± 16
IL-15 132 ± 5 166 ± 7 6031 ± 418 510 ± 82d 111 ± 9
yes none 134 ± 5 150 ± 6 5005 ± 186a 552 ± 34b 122 ± 5 1978 ± 178 16 ± 2
IL-15 135 ± 7 143 ± 8 4945 ± 219a 614 ± 32a 127 ± 14 2070 ± 178 16 ± 3
day 7 no none 111 ± 3 177 ± 4 7944 ± 123 838 ± 54 295 ± 10
IL-15 111 ± 3 169 ± 4 7196 ± 56e 539 ± 52e 290 ± 17
yes none 115 ± 4 99 ± 4c 4098 ± 105c 269 ± 30c 117 ± 6c 4528 ± 156 54 ± 2
IL-15 114 ± 3 111 ± 1c,d 4769 ± 200c,d 246 ± 21c 125 ± 14c 4895 ± 312 57 ± 3
Data are expressed as means ± SEM. Tissue weights are expressed as mg per 100 g of initial body weight. Final body weight excludes tumour weight.
Significance of the differences (Student’s t-test): a = P < 0.05, b = P < 0.01, c = P < 0.001 (vs non-tumour bearers); d = P < 0.05, e = P < 0.01 (vs. non-treated).
n = 4 and 6 for non-tumour and tumour bearers, respectively. WAT = white adipose tissue; BAT = brown adipose tissue
Table 2 Muscle weight
Time Tumour Treatment GSN Soleus Tibialis Heart
day 0 no none 472 ± 5 37.4 ± 0.2 154 ± 2 382 ± 14
day 4 no none 569 ± 15 45.7 ± 1.1 179 ± 1 386 ± 9
no IL-15 598 ± 14 44.3 ± 0.8 182 ± 5 386 ± 7
yes none 523 ± 7a 40.5 ± 1.3a 167 ± 4a 355 ± 7a
yes IL-15 564 ± 9c 43.9 ± 1.8 170 ± 8 358 ± 15
day 7 no none 683 ± 13 52.0 ± 0.3 215 ± 3 532 ± 14
no IL-15 677 ± 13 55.6 ± 1.3 206 ± 5 524 ± 5
yes none 442 ± 13b 37.5 ± 1.0b 140 ± 4b 360 ± 13b
yes IL-15 489 ± 7b,c 42.1 ± 0.9b,d 163 ± 3b,d 387 ± 6b
Data (means ± SEM) are expressed as mg per 100 g body weight. Statistical comparison of the data (Student’s t-test): 
a = P < 0.05, b = P < 0.001 (vs non-tumour bearers); c = P < 0.05, d = P < 0.01 (vs non-treated). n = 4 and 6 for non-tumour
and tumour bearers respectively. GSN = gastrocnemius
Table 3 Tibialis protein content
Time Tumour Treatment mg g–1 tissue mg protein per 100 g ibw
day 4 no none 143 ± 4.4 25.5 ± 0.58
no IL-15 141 ± 2.0 26.2 ± 0.35
yes none 144 ± 3.6 22.7 ± 2.05
yes IL-15 146 ± 1.5 25.2 ± 0.97
day 7 no none 126 ± 1.4 27.0 ± 0.65
no IL-15 129 ± 2.5 26.5 ± 0.56
yes none 108 ± 6.0a 15.3 ± 1.18b
yes IL-15 119 ± 4.6 19.2 ± 0.79b,c
Data are expressed as mean ± SEM. Statistical comparison of the data (Student’s t-test): a = P < 0.05, 
b = P < 0.001 (vs non-tumour bearers); c = P < 0.05 (vs non-treated). n = 4 and 6 for non-tumour and
tumour bearers respectively. ibw = initial body weight.(70%) and synthesis (12%) rates, which resulted in no changes in
protein accumulation (Table 4).
As previously shown (Llovera et al, 1994), the accelerated
muscle protein breakdown in the AH-130 hosts is associated with
activation of the ATP-ubiquitin-dependent proteolytic system.
Two polyubiquitin mRNA species (2.4 kb and 1.2 kb) were found
in tibialis muscle (Figure 1). 7-day tumour-bearing animals
showed an increased expression of the polyubiquitin genes
compared with the corresponding control animals: over 3-fold for
both ubiquitin transcripts. The expression of the C8 proteasome
subunit was also increased as a result of tumour burden (Figure 1).
Control animals receiving IL-15 also showed significant decreases
in the expression of these genes, in agreement with the decreased
protein degradation associated with IL-15 treatment (Table 4). In
addition, when the tumour-bearing animals received IL-15, the
activation of this proteolytic system was also suppressed (Figure
1).
Corticosterone was elevated (day 7) and insulin decreased (days
4 and 7) in the blood plasma of AH-130 hosts at day 7, as previ-
ously observed (Tessitore et al, 1993b). When these animals were
administered IL-15, neither insulin nor corticosterone levels were
significantly affected, suggesting that the effects of the cytokine
were not mediated through these hormones. In non-tumour
bearers, the treatment did not modify insulin concentrations (Table
5).
DISCUSSION
Muscle protein wasting is a prominent feature in cancer cachexia
and is primarily ascribed to enhanced tissue protein catabolism
(Kien and Camitta, 1983; 1987; Beck and Tisdale, 1989; Melville
et al, 1990; Beck et al, 1991; Tessitore et al, 1993a). Most thera-
peutic approaches to cancer cachexia have been designed on the
assumption that tissue wasting merely results from undernutrition
or tumour–host competition, yet parenteral nutrition or over-
feeding have proven to be only marginally or, at best, temporarily
effective (Moley et al, 1988; Popp et al, 1988; Shaw and Wolfe,
1988). Moreover, in some cases the tumour itself apparently took
more advantage of such a treatment than the patient (Tayek et al,
1986; Popp et al, 1988).
The rat tumour model used in the present study quickly causes
progressive body weight loss and tissue protein wasting. The latter
is associated with tissue protein hypercatabolism (TPH) (Tessitore
et al, 1987a; 1987b; 1993a) which is probably mediated by
production of cytokines such as TNF (García-Martínez et al, 1993;
Llovera et al, 1993a, 1993b) and alterations in hormonal home-
ostasis (Tessitore et al, 1993a). The beneficial effects of treatments
with anti-TNF antibodies (Costelli et al, 1993) or with drugs inter-
fering with the development of TPH (Tessitore et al, 1994) have
been previously reported. The present observations show that
treatment of the AH-130 hosts with IL-15 inhibits some of the
protein loss in the tibialis muscle by reverting the increase in
protein degradation. This is consistent with previous reports indi-
cating that IL-15 may act as an anabolic cytokine for skeletal
muscle (Quinn et al, 1995). IL-15 activates NK cells (Carson et al,
1994; 1997), which have anti-tumour properties; however, it has to
be pointed out that IL-15 had no effect on tumour growth in our
model. Thus, the effects of IL-15 on tumour-induced wasting
could not be related to the anti-tumour action of this cytokine.
The precise mechanisms by which intracellular proteins are
degraded are largely unknown, although it is accepted that proteo-
lysis may occur inside and outside the lysosomes. Lysosomal
proteases, in particular cathepsins, are not the major mediators of
myofibrillar protein degradation in rat skeletal muscle (Lowell et
al, 1986; Tessitore et al, 1994). The ATP-ubiquitin-dependent
proteolytic system is postulated to account for the turnover of
short-lived proteins (Ciechanover et al, 1984) or for abnormal
proteins formed during stress such as heat-shock (Bond et al,
1988). However, it has been suggested that the activity of this
IL-15 and cancer cachexia 529
British Journal of Cancer (2000) 83(4), 526–531 © 2000 Cancer Research Campaign
Table 4 Tibialis muscle protein turnover
Time Tumour Treatment ks kd ka
day 4 no none 10.7 ± 0.86 2.77 ± 0.27 7.94 ± 0.63
no IL-15 9.39 ± 1.54 0.82 ± 0.20b 8.22 ± 0.93
yes none 10.6 ± 1.54 4.11 ± 0.82 5.76 ± 1.23
yes IL-15 8.80 ± 0.75 0.49 ± 0.49a,c 8.07 ± 0.98
For further details see Materials and methods. Fractional rates of protein
synthesis (ks), degradation (kd) and accumulation (ka) are expressed as %
per day (n = 5 for each time-point) and were calculated over the time interval
0–4 days. Significance of the differences (Student’s t-test): a = P < 0.01, 
b = P < 0.001 (vs controls); c = P < 0.01 (vs AH-130)
C IL-15
Ub 2.4 kb
Ub 1.2 kb
C8
28S
18S
T T+IL-15
400
2.4 kb
1.2 kb
300
200
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**
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Figure 1 Northern blots of tibialis muscle extracts from tumour-bearing rats.
Expression of ubiquitin and C8 proteasome subunit mRNAs in tibialis
muscles from control (C), control treated with IL-15 (IL-15), 7-day tumour-
bearing (T) and 7-day tumour-bearing treated with IL-15 (T+IL-15). mRNA
was detected after hybridization with a cDNA probe containing a region of the
chicken polyubiquitin gene UB1 or the C8 gene. Autoradiographs were
subjected to scanning densitometry. Ethidium bromide (EtBr) was used for
total RNA quantitation in order to correct the resultssystem can also be related to the turnover of long-lived proteins
such as those found in skeletal muscle (Hilenski et al, 1992).
Recently, this proteolytic system has been involved in the perturba-
tions of protein metabolism in skeletal muscle in many pathological
conditions (see Argilés and López-Soriano, 1996 for review).
Previous studies from our laboratory have shown that the lyso-
somal pathway is only marginally involved in the development of
muscle protein hypercatabolism in the AH-130 hosts (Llovera et al,
1994; 1995; Tessitore et al, 1994), while an important activation of
the ATP-dependent proteolysis seems to be the major mechanism
(Llovera et al, 1994; Costelli et al, 1995). It is very interesting to
observe that the preventive effect exerted by IL-15 on the accelera-
tion of muscle protein breakdown is associated with a normaliza-
tion of the hyperexpression of both the C8 proteasome subunit and
the ubiquitin mRNAs. Moreover, the present observation that IL-15
administration to control rats reduces ubiquitin and C8 mRNAs
expression below the basal values should be stressed. To the best of
our knowledge, this is the first report showing that the effect of IL-
15 on muscle protein turnover may be due to downregulation of the
ATP-ubiquitin-dependent proteolytic system.
The action of the cytokine on muscle protein metabolism in
skeletal muscle might involve hormonal modulations. However, as
far as insulin and corticosterone are concerned, the present study
suggests that this is not the case for the AH-130 hosts, since the
altered plasma level of neither hormone was corrected by the treat-
ment.
Another important action of IL-15 is to reduce the body fat
content by inhibiting lipogenesis (Carbó et al, 2000); tissue-
specific modulations in lipoprotein lipase activity could provide an
additional mechanism for promoting a decreased lipid accretion in
adipose tissue. The present cachexia model is itself characterized
by extensive lipid mobilization (Dessì et al, 1992; Carbó et al,
1994), associated with decreased activity of tissue lipoprotein
lipase (Carbó et al, 1994). The lack of effect of IL-15 on adipose
tissue in AH-130 hosts may thus reflect the fact that lipid mobi-
lization was already occurring in these animals and could not
easily be stimulated further. When the cytokine treatment was
applied to control rats, however, adipose tissue mass decreased
with respect to untreated controls (by 34%), in agreement with
previous reports (Carbó et al, 2000).
In conclusion, the present results indicate that IL-15 exerted a
selective, protective action on skeletal muscle by antagonizing
both the enhanced protein degradation and, to some extent the
resulting protein loss, which characterize cachexia in AH-130
tumour-bearing rats. These observations suggest that the cytokine
could be a convenient therapeutic tool in pathological states where
muscle protein hypercatabolism is a critical feature, such as cancer
cachexia or other wasting diseases.
ACKNOWLEDGEMENTS
Work supported by grants from the Fondo de Investigaciones
Sanitarias de la Seguridad Social (97/2059) of the Spanish Health
Ministry, the Dirección General de Investigación Científica y
Técnica (PB94-0938 and HI-1996–0049) from the Spanish
Ministry of Education and Science, the Ministero dell’Università e
della Ricerca Scientifica e Tecnologica (60% and 40% funds),
Roma, the Consiglio Nazionale delle Ricerche (Special Project
ACRO), Roma, the Associazione Italiana per la Ricerca sul
Cancro, Milano. The authors would like to thank Immunex
Corporation (Seattle, WA, USA), which kindly provided IL-15,
and Dr MJ Schlesinger and Dr K Tanaka for providing the ubiq-
uitin-specific and proteasome C8 probes, respectively.
REFERENCES
Akbar AN, Borthwick NJ, Wickremashinge RG, Panayoitidis P, Pilling D, Bofill M,
Krajewski S, Reed JC and Salmon M (1996) IL-2 receptor g-chain signalling
cytokines regulate activated T-cell apoptosis in response to growth factor
withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-XL) but not
proapoptotic (bax, bcl-XS) gene expression. Eur J Immunol 26: 294–299
Albano JDM, Ekins RP, Maritz G and Turner RC (1972) A sensitive and precise
radioimmunoassay of serum insulin. Acta Endocrinol 70: 487–509
Argilés JM and López-Soriano FJ (1996) The ubiquitin-dependent proteolytic
pathway in skeletal muscle: its role in pathological states. Trends Pharmacol
Sci 17: 223–226
Armitage RJ, Macduff BM, Eisenman J, Paxton R and Grabstein KH (1995) IL-15
has stimulatory activity for the induction of B cell proliferation and
differentiation. J Immunol 154: 483–490
Baccino FM, Tessitore L, Bonelli G and Isidoro C (1986) Protein turnover states of
tumour cells and host tissues in an experimental model. Biomed Biochim Acta
45: 1585–1590
Beck SA and Tisdale MJ (1989) Nitrogen excretion in cancer cachexia and its
modification by a high fat diet in mice. Cancer Res 49: 3800–3804
Beck SA, Smith KL and Tisdale MJ (1991) Anticachectic and antitumour effect of
eicosapentaenoic acid and its effect on protein turnover. Cancer Res 51:
6089–6093
Bond U and Schlesinger MJ (1985) Ubiquitin is a heat-shock protein in chicken-
embryo fibroblasts. Mol Cell Biol 5: 949–956
Bond U, Agell N, Haas AL, Redman K and Schlesinger MJ (1988) Ubiquitin in
stressed chicken embryo fibroblasts. J Biol Chem 263: 2384–2388
Bradford MM (1976) A rapid and sensitive method for the quantification of
microgram quantities of protein utilizing the principle protein-dye binding.
Anal Biochem 72: 248–254
Bruton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J,
Roessler E and Waldmann TA (1994) A lymphokine, provisionally designated
interleukin T and produced by a human adult T cell leukemia line, stimulates T
cell proliferation and the induction of lymphokine-activated killer cells. Proc
Natl Acad Sci USA 91: 4935–4939
Bulfone-Paus S, Ungureanu D, Pohl T, Lindner G, Paus R, Ruckert R, Krause H and
Kunzendorf U (1997) Interleukin-15 protects from lethal apoptosis in vivo.
Nature Med 3: 1124–1128
Carbó N, Costelli P, Tessitore L, Bagby GJ, López-Soriano FJ, Baccino FM and
Argilés JM (1994) Anti-TNF treatment interferes with changes in lipid
metabolism in a tumour cachexia model. Clin Sci 87: 349–355
Carbó N, López-Soriano J, Costelli P, Alvarez B, Busquets S, Baccino FM, Quinn
LS, López-Soriano FJ and Argilés JM (2000) Interleukin-15 mediates
reciprocal regulation of adipose tissue and muscle mass: a potential role in
body weight control. Submitted to publication
Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D,
Eisenman J, Grabstein K and Caligiuri MA (1994) Interleukin (IL) 15 is a
novel cytokine that activates human natural killer cells via components of the
IL-2 receptor. J Exp Med 180: 1395–1403
530 N Carbó et al
British Journal of Cancer (2000) 83(4), 526–531 © 2000 Cancer Research Campaign
Table 5 Plasma levels of insulin and corticosterone
Time Tumor Treatment Corticosterone Insulin
(ng ml–1) (ng ml–1)
days 4–7 no none 130 ± 15 2.31 ± 0.66
day 4 no IL-15 77 ± 7c 1.78 ± 0.63
yes none 234 ± 95 1.08 ± 0.32a
yes IL-15 120 ± 22 0.71 ± 0.05a
day 7 no IL-15 203 ± 22c 2.78 ± 0.66
yes none 824 ± 178b 1.57 ± 0.05a
yes IL-15 557 ± 107b 1.67 ± 0.17a
Data are means ± S.E.M. Significance of the differences (Student’s t test): 
a = P < 0.05, b = P < 0.001 (vs control days 4–7); c = P < 0.05 (vs non-
treated). n = 4 and 6 for non- tumour and tumour bearers respectivelyIL-15 and cancer cachexia 531
British Journal of Cancer (2000) 83(4), 526–531 © 2000 Cancer Research Campaign
Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM,
Baumann H and Caligiuri MA (1997) A potential role for interleukin-15 in the
regulation of human natural killer cell survival. J Clin Invest 99: 937–943
Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid
guanidinium thiocyanate phenol chloroform extraction. Anal Biochem 162:
156–159
Ciechanover A, Finley D and Varshavsky A (1984) Ubiquitin dependence of
selective protein degradation demonstrated in the mammalian cell cycle mutant
ts85. Cell 37: 57–66
Costelli P, Carbó N, Tessitore L, Bagby GJ, López-Soriano FJ, Argilés JM and
Baccino FM (1993) Tumour necrosis factor-a mediates changes in protein
turnover in a rat cancer cachexia model. J Clin Invest 92: 2783–2789
Costelli P, García-Martínez C, Llovera M, Carbó N, López-Soriano FJ, Agell N,
Tessitore L, Baccino FM and Argilés JM (1995) Muscle protein waste in
tumor-bearing rats is effectively antagonized by a b2-adrenergic agonist
(clenbuterol). J Clin Invest 95: 2367–2372
Dessì S, Batetta B, Anchisi C, Pani P, Costelli P, Tessitore L and Baccino FM (1992)
Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida
AH-130). Br J Cancer 66: 787–793
Emery PW, Neville AM, Edwards RHT and Rennie MJ (1982) Increased
myofibrillar degradation and decreased protein synthesis in tumor-bearing
mice. Eur J Clin Invest 12: 10
García-Martínez C, López-Soriano FJ and Argilés JM (1993) Acute treatment with
tumour necrosis factor-a induces changes in protein metabolism in rat skeletal
muscle. Mol Cell Biochem 125: 11–18
Garlick PJ, Millward DJ, James WPT and Waterlow JC (1975) The effect of protein
deprivation and starvation on the rate of protein synthesis in tissues of the rat.
Biochim Biophys Acta 414: 71–84
Girard D, Paquet ME, Paquin R and Beaulieu AD (1996) Differential effects of
interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of
phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by
IL-15. Blood 88: 3176–3184
Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, Namen A,
Park LS, Cosman D and Anderson D (1994) Utilization of the b and g chain of
the IL-2 receptor by the novel cytokine IL-15. EMBO J 13: 2822–2830
Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C,
Richardson J, Schoenborn MA, Ahdieh M, Johnson L, Alderson MR, Watson
JD, Anderson DM and Giri JG (1994) Cloning of a T cell growth factor that
interacts with the b chain of the interleukin-2 receptor. Science 264: 965–968
Hilenski LL, Terracio L, Haas AL and Borg TK (1992) Immunolocalization of
ubiquitin conjugates at Z-bands and intercalated discs of rat cardiomyocytes in
vitro and in vivo. J Histochem Cytochem 40: 1037–1042
Kien CL and Camitta BM (1983) Increased whole-body protein turnover in children
with newly diagnosed leukemia or lymphoma. Cancer Res 43: 5592–5596
Kien CL and Camitta BM (1987) Close association of accelerated rates of whole
body protein turnover (synthesis and breakdown) and energy expenditure in
children with newly diagnosed acute lymphocytic leukaemia. J Parent Enteral
Nutr 11: 129–134
Lawson DH, Richmond A, Nixon DW and Rudman D (1982) Metabolic approaches
to cancer cachexia. Annu Rev Nutr 2: 277–301
Llovera M, López-Soriano FJ and Argilés JM (1993a) Effects of tumour necrosis
factor-a on muscle protein turnover in vivo in female rats. J Natl Cancer Inst
85: 1334–1339
Llovera M, López-Soriano FJ and Argilés JM (1993b) Chronic tumour necrosis
factor-a treatment modifies protein turnover in rat tissues. Biochem Mol Biol
Int 30: 29–36
Llovera M, García-Martínez C, Agell N, Marzábal M, López-Soriano FJ and Argilés
JM (1994) Ubiquitin gene expression is increased in skeletal muscle of tumour-
bearing rats. FEBS Lett 338: 311–318
Llovera M, Garcia-Martínez C, Agell N, López-Soriano FJ and Argilés JM (1995)
Muscle wasting associated with cancer cachexia is linked to an important
activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer
61: 138–141
Lowell BB, Ruderman NB and Goodman MN (1986) Evidence that lysosomes are
not involved in the degradation of myofibrillar proteins in rat skeletal muscle.
Biochem J 234: 237–240
Lundholm K, Ekman D, Edstrom S, Karlberg I, Jagenberg R and Scherstén T (1979)
Protein synthesis in liver tissue under the influence of a methyl-cholanthrene-
induced sarcoma in mice. Cancer Res 39: 4657–4661
Melville S, McNurlan MA, Graham Calder A and Garlick PJ (1990) Increased
protein turnover despite normal energy metabolism and responses to feeding in
patients with lung cancer. Cancer Res 50: 1125–1131
Moley JF, Morrison SD, Gorschboth CM and Norton JA (1988) Body composition
changes in rats with experimental cancer cachexia: improvement with
exogenous insulin. Cancer Res 48: 2784–2787
Morrison SD (1989) Cancer cachexia. In Influence of Tumor Development on the
Host (Liotta AL, ed), pp. 176–213. Kluwer Academic Publ., The
Netherlands.
Munger W, DeJoy SQ, Jeyaseelan R Sr, Torley LW, Grabstein KH, Eisenman J,
Paxton R, Cox T, Wick MM and Kerwar SS (1995) Studies evaluating the
antitumor activity and toxicity of interleukin-15, a new T cell growth factor:
comparison with interleukin-2. Cell Immunol 165: 289–293
Pain VM, Randall DP and Garlick PJ (1984) Protein synthesis in liver and skeletal
muscle of mice bearing an ascites tumor. Cancer Res 44: 1054–1057
Popp MB, Wagner SC, Enrione EB and Brito OJ (1988) Host and tumor responses to
varying rates of nitrogen infusion in the tumor-bearing rat. Ann Surg 207:
80–89
Quinn LS, Haugk KL and Grabstein KH (1995) Interleukin-15: a novel anabolic
cytokine for skeletal muscle. Endocrinology 136: 3669–3672
Reinecker HC, MacDermott RP, Mirau S, Dignass A and Podolsky DK (1996)
Intestinal epithelial cells both express and respond to interleukin-15.
Gastroenterology 111: 1706–1713
Shaw JH and Wolfe RR (1988) Whole-body protein kinetics in patients with early
and advanced gastrointestinal cancer: the early response to glucose infusion
and total parenteral nutrition. Surgery 103: 148–155
Tanaka K, Kanamaya H, Tamura T, Lee DH, Kumatori A, Fujiwara T, Ichihara A,
Tokunaga F, Aruga R and Iwanaga S (1990) cDNA cloning and sequencing of
component C8 of proteasomes from rat hepatoma cells. Biochem Biophys Res
Commun 171: 676–683
Tayek JA, Istfan NW, Jones CT, Hamawy KJ, Bistrian BR and Blackburn GL (1986)
Influence of the Walker 256 carcinosarcoma on muscle, tumor, and whole-body
protein synthesis and growth rate in the cancer-bearing rat. Cancer Res 46:
5649–5654
Tessitore L, Bonelli G, Isidoro C, Kazakova OV and Baccino FM (1986)
Comparative studies of protein turnover regulations in tumor cells and host
tissues: development and analysis of an experimental model. Toxicol Pathol
14: 451–456
Tessitore L, Bonelli G and Baccino FM (1987a) Early development of protein
metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats.
Biochem J 241: 153–159
Tessitore L, Bonelli G, Cecchini G, Amenta JS and Baccino FM (1987b)
Regulation of protein turnover versus growth state: ascites hepatoma as a
model for studies both in the animal and in vitro. Arch Biochem Biophys 255:
372–384
Tessitore L, Costelli P, Bonetti G and Baccino FM (1993a) Cancer cachexia,
malnutrition, and tissue protein turnover in experimental animals. Arch
Biochem Biophys 306: 52–58
Tessitore L, Costelli P and Baccino FM (1993b) Humoral mediation for cancer
cachexia in tumour-bearing rats. Br J Cancer 67: 15–23
Tessitore L, Costelli P and Baccino FM (1994) Pharmacological interference with
tissue hypercatabolism in tumour-bearing rats. Biochem J 299: 71–78
Tisdale MJ (1992) Cancer cachexia. Br J Cancer 63: 337–342